NCT07503613
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Enrolling by Invitation
Not specifiedAges 18+ObservationalAkouos, Inc.
~100 participants
Updated 2026-07-16 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long term safety of AAVAnc80-antiVEGF, including late-occurring adverse events (AEs
Measured over Through study completion, approximately four years.
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Aaron Tward, MD · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Individual with vestibular schwannoma who received an intracochlear administration of
Participant willingness to comply with all study requirements as evidenced by successful completion of the informed consent process.
Exclusion
Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study and/or, in the opinion of the Investigator, makes the potential participant unsuitable for the study.
What this trial measures
- Long term safety of AAVAnc80-antiVEGF, including late-occurring adverse events (AEsThrough study completion, approximately four years.
1. the development of new or exacerbation of malignancies (oncologic), neurologic, rheumatologic or other autoimmune, hematologic disorders, or new infections (if the infection is potentially related to AAVAnc80-antiVEGF) 2. AEs that are related to the IMP and/or the administration procedure 3. AEs of special interest 4. all serious adverse events, regardless of severity